Anti-NFkB p65 (phospho S529) antibody (ab84333)

Overview

• Product nameAnti-NFkB p65 (phospho S529) antibodySee all NFkB p65 primary antibodies ...
• Description
  Rabbit polyclonal to NFkB p65 (phospho S529)
• Tested applicationsWB more details
• Species reactivity
  Reacts with: Human
  Predicted to work with: Chimpanzee, Macaque Monkey, Gorilla, Orangutan
• Immunogen

  Synthetic peptide conjugated to KLH derived from within residues 500 to the C-terminus of Human NFkB p65.

  Read Abcam's proprietary immunogen policy

  (Peptide available as ab101479.)

• Positive controlThis antibody gave a positive signal in the following whole cell lysates: HeLa; HeLa Nuclear; A431.

Properties

• FormLiquid
• Storage instructionsStore at +4°C short term (1-2 weeks). Aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles.
• Storage bufferPreservative: 0.02% Sodium Azide
  Constituents: 1% BSA, PBS, pH 7.4
• Concentration information loading...
• Purity70 - 90% by HPLC
• Clonality Polyclonal
• IsotypeIgG
• Research Areas
  • Metabolism
  • Types of disease
  • Obesity

  • Cancer
  • Signal transduction
  • Nuclear signaling
  • NFkB pathway

  • Signal Transduction
  • Signaling Pathway
  • Nuclear Signaling
  • NFkB Pathway

  • Cardiovascular
  • Atherosclerosis
  • Vascular Inflammation
  • Inflammatory mediators

  • Microbiology
  • Interspecies Interaction
  • Host Virus Interaction

  • Microbiology
  • Interspecies Interaction
  • Host Immune Response

  • Epigenetics and Nuclear Signaling
  • Nuclear Signaling Pathways
  • NFkB pathway

  • Neuroscience
  • Neurology process
  • Neurodegenerative disease
  • Alzheimer's disease
  • Other

  • Cell Biology
  • Apoptosis
  • Intracellular
  • NFkB
  • RelA (p65)

Applications

Target

• FunctionNF-kappa-B is a pleiotropic transcription factor which is present in almost all cell types and is involved in many biological processed such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52 and the heterodimeric p65-p50 complex appears to be most abundant one. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway, I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators, subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. NF-kappa-B heterodimeric p65-p50 and p65-c-Rel complexes are transcriptional activators. The NF-kappa-B p65-p65 complex appears to be involved in invasin-mediated activation of IL-8 expression. The inhibitory effect of I-kappa-B upon NF-kappa-B the cytoplasm is exerted primarily through the interaction with p65. p65 shows a weak DNA-binding site which could contribute directly to DNA binding in the NF-kappa-B complex. Associates with chromatin at the NF-kappa-B promoter region via association with DDX1.
• Sequence similaritiesContains 1 RHD (Rel-like) domain.
• Domainthe 9aaTAD motif is a transactivation domain present in a large number of yeast and animal transcription factors.
• Post-translational
  modificationsUbiquitinated, leading to its proteasomal degradation. Degradation is required for termination of NF-kappa-B response.
  Monomethylated at Lys-310 by SETD6. Monomethylation at Lys-310 is recognized by the ANK repeats of EHMT1 and promotes the formation of repressed chromatin at target genes, leading to down-regulation of NF-kappa-B transcription factor activity. Phosphorylation at Ser-311 disrupts the interaction with EHMT1 without preventing monomethylation at Lys-310 and relieves the repression of target genes.
  Phosphorylation at Ser-311 disrupts the interaction with EHMT1 and promotes transcription factor activity (By similarity). Phosphorylation on Ser-536 stimulates acetylation on Lys-310 and interaction with CBP; the phosphorylated and acetylated forms show enhanced transcriptional activity.
  Reversibly acetylated; the acetylation seems to be mediated by CBP, the deacetylation by HDAC3. Acetylation at Lys-122 enhances DNA binding and impairs association with NFKBIA. Acetylation at Lys-310 is required for full transcriptional activity in the absence of effects on DNA binding and NFKBIA association. Acetylation can also lower DNA-binding and results in nuclear export. Interaction with BRMS1 promotes deacetylation of 'Lys-310'.
• Cellular localizationNucleus. Cytoplasm. Nuclear, but also found in the cytoplasm in an inactive form complexed to an inhibitor (I-kappa-B). Colocalized with RELA in the nucleus upon TNF-alpha induction.

Target information above from: UniProt accession Q04206 The UniProt Consortium
The Universal Protein Resource (UniProt) in 2010
Nucleic Acids Res. 38:D142-D148 (2010) .

Information by UniProt
• Database links
  • Entrez Gene: 5970 Human
  • Omim: 164014 Human
  • SwissProt: Q04206 Human
  • Unigene: 502875 Human

• Alternative names
  Avian reticuloendotheliosis viral (v rel) oncogene homolog A antibodyMGC131774 antibodyNF kappa B p65delta3 antibody

  NFKB3 antibodyNuclear Factor NF Kappa B p65 Subunit antibodyNuclear factor NF-kappa-B p65 subunit antibodyNuclear factor of kappa light polypeptide gene enhancer in B cells 3 antibodyNuclear factor of kappa light polypeptide gene enhancer in B-cells 3 antibodyOTTHUMP00000233473 antibodyOTTHUMP00000233474 antibodyOTTHUMP00000233475 antibodyOTTHUMP00000233476 antibodyOTTHUMP00000233900 antibodyp65 antibodyp65 NF kappaB antibodyp65 NFkB antibodyRELA antibodyTF65_HUMAN antibodyTranscription Factor p65 antibodyv rel avian reticuloendotheliosis viral oncogene homolog A (nuclear factor of kappa light polypeptide gene enhancer in B cells 3 (p65)) antibodyv rel reticuloendotheliosis viral oncogene homolog A (avian) antibodyv rel reticuloendotheliosis viral oncogene homolog A antibodyV rel reticuloendotheliosis viral oncogene homolog A, nuclear factor of kappa light polypeptide gene enhancer in B cells 3, p65 antibody

  see all

Anti-NFkB p65 (phospho S529) antibody images

• 

  Western blot - NFkB p65 (phospho S529) antibody (ab84333)
  All lanes : Anti-NFkB p65 (phospho S529) antibody (ab84333) at 1 µg/ml
  
  Lane 1 : HeLa (Human epithelial carcinoma cell line) Whole Cell Lysate with NFkB p65 peptide (ab116684)
  Lane 2 : HeLa (Human epithelial carcinoma cell line) Nuclear Lysate with NFkB p65 peptide (ab116684)
  Lane 3 : A431 (Human epithelial carcinoma cell line) Whole Cell Lysate with NFkB p65 peptide (ab116684)
  Lane 4 : HeLa (Human epithelial carcinoma cell line) Whole Cell Lysate with NFkB p65 peptide - phospho S529 (ab101479)
  Lane 5 : HeLa (Human epithelial carcinoma cell line) Nuclear Lysate with NFkB p65 peptide - phospho S529 (ab101479)
  Lane 6 : A431 (Human epithelial carcinoma cell line) Whole Cell Lysate with NFkB p65 peptide - phospho S529 (ab101479)
  
  Lysates/proteins at 10 µg per lane.
  Blocking peptides at 1 µg/ml per lane.
  
  Secondary
  Goat polyclonal to Rabbit IgG - H&L - Pre-Adsorbed (HRP) at 1/3000 dilution
  developed using the ECL technique
  
  Performed under reducing conditions.
  
  Predicted band size : 60 kDa
  Observed band size : 56 kDa (why is the actual band size different from the predicted?)
  
  
  Exposure time : 20 minutes